Adult rats of both sexes were given a single oral dose of [14C] patulin and were sacrificed at various time intervals from 4 hr to 7 days following administration of the mycotoxin. Two groups of rats were employed; the treated group had been exposed to daily oral doses of unlabeled patulin (dissolved in pH 5.0 citrate buffer) in utero and for 41-66 wk after weaning, while the controls were given the buffer only throughout gestation and for 38-81 wk after weaning. Approximately 49% of the administered 14C radioactivity was recovered from feces and 36% from urine within 7 days after dosing. Most of the excretion of labeled material occurred within the first 24 hr. All of the 14C activity detected in the urine samples was either metabolites and/or conjugates of the original [14C]patulin. About 1-2% of the total radioactivity was recovered as 14CO2 from expired air. Carbon-14 radioactivity in various tissues and organs was determined throughout the 7 day period; the most significant retention site was the red blood cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15287397709529580 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recovered water - HO from the F[FDG] production as liquid radioactive waste.
Appl Radiat Isot
January 2025
Department of Medical Physics, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Lodz, Poland; Department of Medical Imaging Technology, Medical University of Lodz, Ul. Lindleya 6, 90-131, Łódź, Poland.
In this study, ten recovered water samples were analysed using gamma spectrometry and Liquid Scintillation Counting techniques for identification of radioactive impurities (quality and quantity) and for radioactive waste qualifications. The presence of several radioactive isotopes of H, Co Mn in the recovered [O] water irradiated with 11 MeV protons used to produce [F] fluoride by the O(p,n)F reaction has been confirmed. Radioactive impurities were generated directly in enriched water or washed out from activated Havar foil, or tantalum body target material.
View Article and Find Full Text PDFFrom Radioactive Effluent to Drinking Water: Efficient Removal of Trace TcO /ReO by Cationic Porous Aromatic Framework.
Adv Sci (Weinh)
January 2025
Department of Chemistry, University of North Texas1508 W Mulberry St, Denton, TX, 76201, USA.
Efficient removal of TcO from radioactive effluents while recovering drinking water remains a challenge. Herein, an excellent ReO (a nonradioactive surrogate of TcO ) scavenger is presented through covalently bonding imidazolium poly(ionic liquids) polymers with an ionic porous aromatic framework (iPAF), namely iPAF-P67, following an adsorption-site density-addition strategy. It shows rapid sorption kinetics, high uptake capacity, and exceptional selectivity toward ReO .
View Article and Find Full Text PDFMass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation.
Eur J Drug Metab Pharmacokinet
December 2024
Preclinical Development-Drug Metabolism and Pharmacokinetics, Bayer AG, Berlin, Germany.
Background: Elinzanetant is a dual neurokinin-1,3 receptor antagonist in development for the treatment of menopausal vasomotor symptoms. The objectives of these studies were to characterize the mass balance and biotransformation of elinzanetant.
Methods: In the clinical evaluation, whole blood, plasma, urine, and feces were collected from healthy fasted male volunteers (n = 6) following a single dose of 120 mg [C]-elinzanetant oral suspension for analysis of total radioactivity and metabolite profiling.
Mass balance, metabolic disposition, and pharmacokinetics of a single IV dose of [14C]CA102N in HT-29 xenograft athymic nude mice.
Front Pharmacol
December 2024
Holy Stone Healthcare, Preclinical and Development Div Hsinchu, Taipei, Taiwan.
Introduction: CA102N is a novel anticancer drug developed by covalently linking H-Nim (N-(4-Amino-2-phenoxyphenyl methanesulfonamide) to Hyaluronic Acid to target CD44 receptor-rich tumors. The proposed approach seeks to enhance the efficacy and overcome limitations associated with H-Nim, including poor solubility and short half-life.
Methods: The study aimed to evaluate the pharmacokinetics, biodistribution, metabolism, and tumor permeability of [14C] CA102N in xenograft mice following a single intravenous dose of 200 mg/kg.
Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRAS inhibitor.
Cancer Chemother Pharmacol
December 2024
Clinical Pharmacology and Nonclinical Development, Mirati Therapeutics Inc., San Diego, CA, USA.
Objective: This study investigated absorption, metabolism, and excretion of adagrasib after a single oral 600 mg dose (1 µCi [C]-adagrasib) in 7 healthy subjects and compared the metabolite profile to the profile at steady-state in 4 patients dosed at 600 mg twice daily.
Methods: Plasma, urine, and feces were collected post [C]-adagrasib administration and total radioactivity and pooled sample metabolite profiles were determined. Adagrasib pharmacokinetics were determined in plasma and urine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!